JNJ-90301900 + durvalumab + carboplatin + paclitaxel

A combination regimen consisting of four agents: - **JNJ-90301900** (also known as NBTXR3), an injectable radioenhancer nanoparticle designed to enhance the effect of radiotherapy by amplifying localized energy deposition and cell killing. - **Durvalumab**, a monoclonal antibody immune checkpoint inhibitor that blocks PD-L1, boosting anti-tumor immune responses. - **Carboplatin**, a platinum-based chemotherapy agent that induces DNA crosslinking and causes apoptosis in rapidly dividing cells. - **Paclitaxel**, a microtubule inhibitor chemotherapeutic that disrupts mitosis and leads to cancer cell death. The regimen is under investigation for treating locally advanced and unresectable stage III non-small cell lung cancer in combination with chemoradiation followed by consolidation immunotherapy[1][7].

Brand names

Imfinzi (for durvalumab)